D Lenihan1, T Suter2, M Brammer3, C Neate4, G Ross5, J Baselga6. 1. Department of Cardiovascular Medicine, Vanderbilt University, Nashville, USA. Electronic address: daniel.lenihan@vanderbilt.edu. 2. Department of Cardiology, Cardio-Oncology, Bern University Hospital and University of Bern, Bern, Switzerland. 3. US Medical Affairs, BioOncology, Genentech, Inc., South San Francisco, USA. 4. Pharmaceutical Development, Biostatistics. 5. Pharmaceutical Development Oncology, Roche Products Ltd, Welwyn Garden City, UK. 6. Department of Medicine, Harvard Medical School; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, USA.
Abstract
BACKGROUND: Pertuzumab, a human epidermal growth factor receptor (HER) 2 dimerization inhibitor, has demonstrated promising efficacy in combination with trastuzumab in patients with metastatic breast cancer. As HER signaling pathways are not only involved in oncogenesis, but also in myocardial homeostasis, an analysis of cardiac safety data was undertaken in a large group of patients treated with pertuzumab. PATIENTS AND METHODS: A complete database of patients treated with full-dose pertuzumab was used to describe the incidence of asymptomatic left ventricular systolic dysfunction (LVSD) and symptomatic heart failure (HF). RESULTS: Information for 598 unique patients was available for the current analysis. Of the patients treated with pertuzumab alone (n = 331) or pertuzumab in combination with a non-anthracycline-containing cytotoxic (n = 175) or trastuzumab (n = 93), 23 (6.9%), 6 (3.4%), and 6 (6.5%), respectively, developed asymptomatic LVSD and 1 (0.3%), 2 (1.1%), and 1 (1.1%), respectively, displayed symptomatic HF. None of the 15 patients receiving both pertuzumab and erlotinib demonstrated LVSD. CONCLUSIONS: Patients treated with pertuzumab experienced relatively low levels of asymptomatic LVSD or symptomatic HF. There was no notable increase in cardiac side-effects when pertuzumab was given in combination with other anticancer agents.
BACKGROUND:Pertuzumab, a humanepidermal growth factor receptor (HER) 2 dimerization inhibitor, has demonstrated promising efficacy in combination with trastuzumab in patients with metastatic breast cancer. As HER signaling pathways are not only involved in oncogenesis, but also in myocardial homeostasis, an analysis of cardiac safety data was undertaken in a large group of patients treated with pertuzumab. PATIENTS AND METHODS: A complete database of patients treated with full-dose pertuzumab was used to describe the incidence of asymptomatic left ventricular systolic dysfunction (LVSD) and symptomatic heart failure (HF). RESULTS: Information for 598 unique patients was available for the current analysis. Of the patients treated with pertuzumab alone (n = 331) or pertuzumab in combination with a non-anthracycline-containing cytotoxic (n = 175) or trastuzumab (n = 93), 23 (6.9%), 6 (3.4%), and 6 (6.5%), respectively, developed asymptomatic LVSD and 1 (0.3%), 2 (1.1%), and 1 (1.1%), respectively, displayed symptomatic HF. None of the 15 patients receiving both pertuzumab and erlotinib demonstrated LVSD. CONCLUSIONS:Patients treated with pertuzumab experienced relatively low levels of asymptomatic LVSD or symptomatic HF. There was no notable increase in cardiac side-effects when pertuzumab was given in combination with other anticancer agents.
Authors: Douglas B Sawyer; Christian Zuppinger; Thomas A Miller; Hans M Eppenberger; Thomas M Suter Journal: Circulation Date: 2002-04-02 Impact factor: 29.690
Authors: Luca Gianni; Anna Lladó; Giulia Bianchi; Javier Cortes; Pirkko-Liisa Kellokumpu-Lehtinen; David A Cameron; David Miles; Stefania Salvagni; Andrew Wardley; Jean-Charles Goeminne; Veronica Hersberger; José Baselga Journal: J Clin Oncol Date: 2010-02-01 Impact factor: 44.544
Authors: Sharmila Makhija; Lukas C Amler; Dana Glenn; Frederick R Ueland; Michael A Gold; Don S Dizon; Virginia Paton; Chin-Yu Lin; Thomas Januario; Kimmie Ng; Andreas Strauss; Stephen Kelsey; Mark X Sliwkowski; Ursula Matulonis Journal: J Clin Oncol Date: 2009-11-09 Impact factor: 44.544
Authors: Werner Scheuer; Thomas Friess; Helmut Burtscher; Birgit Bossenmaier; Josef Endl; Max Hasmann Journal: Cancer Res Date: 2009-12-15 Impact factor: 12.701
Authors: S B Kaye; C J Poole; A Dańska-Bidzińska; L Gianni; G Del Conte; V Gorbunova; E Novikova; A Strauss; M Moczko; V A McNally; G Ross; I Vergote Journal: Ann Oncol Date: 2012-09-20 Impact factor: 32.976
Authors: Thomas M Suter; Marion Procter; Dirk J van Veldhuisen; Michael Muscholl; Jonas Bergh; Chiara Carlomagno; Timothy Perren; Rodolfo Passalacqua; Claudia Bighin; Jan G M Klijn; Fail T Ageev; Erika Hitre; Juergen Groetz; Hiroji Iwata; Malgorzata Knap; Michael Gnant; Susanne Muehlbauer; Alison Spence; Richard D Gelber; Martine J Piccart-Gebhart Journal: J Clin Oncol Date: 2007-07-23 Impact factor: 44.544
Authors: Gustavo A Viani; Sergio L Afonso; Eduardo J Stefano; Ligia I De Fendi; Francisco V Soares Journal: BMC Cancer Date: 2007-08-08 Impact factor: 4.430
Authors: Hui-Ming Chang; Rohit Moudgil; Tiziano Scarabelli; Tochukwu M Okwuosa; Edward T H Yeh Journal: J Am Coll Cardiol Date: 2017-11-14 Impact factor: 24.094
Authors: Carlos L Arteaga; Mark X Sliwkowski; C Kent Osborne; Edith A Perez; Fabio Puglisi; Luca Gianni Journal: Nat Rev Clin Oncol Date: 2011-11-29 Impact factor: 66.675
Authors: Sandra M Swain; Michael S Ewer; Javier Cortés; Dino Amadori; David Miles; Adam Knott; Emma Clark; Mark C Benyunes; Graham Ross; José Baselga Journal: Oncologist Date: 2013-03-08
Authors: Chiara D'Avino; Rolando Paciello; Gennaro Riccio; Carmela Coppola; Melina Coppola; Paolo Laccetti; Nicola Maurea; Ronald T Raines; Claudia De Lorenzo Journal: Protein Eng Des Sel Date: 2014-01-12 Impact factor: 1.650